EUVIMEDEUVIMED entdecken
Crossref

Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes

Zucheng Xie, Yan Qin, Xinrui Chen, Sheng Yang, Jianliang Yang, Lin Gui, Peng Liu, Xiaohui He, Shengyu Zhou, Changgong Zhang, Le Tang, Yuankai Shi iD

Targeted Oncology · 2024

DOI: 10.1007/s11523-024-01057-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Targeted Oncology, 2024. Verfasst von Zucheng Xie und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clin…. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Myeloid Differentiation Factor 88, CD79 Antigens, Mutation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Science and Technology Major Project for Key New Drug Development, Beijing Municipal Social Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The clinical and genetic characteristics, as well as treatment outcomes, of diffuse large B-cell lymphoma (DLBCL) patients with different MYD88 and CD79B mutation status merit further investigation. OBJECTIVE: This study aims to investigate the distinctions in clinical manifestations, genetic characteristics, and treatment outcomes among MYD88-CD79Bco-mut, MYD88/CD79Bsingle-mut, and MYD88-CD79Bco-wt DLBCL patients. PATIENTS AND METHODS: Clinical and genetic characteristics, along with treatment outcomes among 2696 DLBCL patients bearing MYD88-CD79Bco-mut, MYD88/CD79Bsingle-mut, and MYD88-CD79Bco-wt treated with R-CHOP/R-CHOP-like regimens from the Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College and six external cohorts were analyzed. Potential molecular mechanisms were investigated through Gene Set Enrichment Analysis and xCell methodology. RESULTS: In the MCD subtype, patients with MYD88-CD79Bco-mut showed comparable progression-free survival (PFS) and overall survival (OS) compared to MYD88/CD79Bsingle-mut or MYD88-CD79Bco-wt. However, in the non-MCD subtype, patients with MYD88-CD79Bco-mut exhibited significantly inferior OS than MYD88/CD79Bsingle-mut or MYD88-CD79Bco-wt, while there was no significant OS difference between MYD88/CD79Bsingle-mut and MYD88-CD79Bco-wt (median OS: 68.8 [95% CI 22-NA] vs NA [95% CI 112-NA] vs 177.7 [95% CI 159-NA] months; MYD88-CD79Bco-mut vs MYD88/CD79Bsingle-mut: p = 0.02; MYD88-CD79Bco-mut vs MYD88-CD79Bco-wt: p = 0.03; MYD88/CD79Bsingle-mut vs MYD88-CD79Bco-wt: p = 0.33). Regarding patients with MYD88-CD79Bco-mut, there was no significant difference in PFS and OS between the MCD and non-MCD subtypes. Within the MYD88-CD79Bco-mut group, patients with PIM1mut had better PFS than PIM1wt (median PFS: 8.34 [95% CI 5.56-NA] vs 43.8 [95% CI 26.4-NA] months; p = 0.02). Possible mechanisms contributing to the superior PFS of PIM1mut patients may include activated lymphocyte-mediated immunity and interferon response, a higher proportion of natural killer T cells and plasmacytoid dendritic cells, as well as suppressed angiogenesis and epithelial-mesenchymal transition, along with lower fibroblast and stromal score. CONCLUSIONS: In the MCD subtype, patients with MYD88-CD79Bco-mut showed comparable PFS and OS compared to MYD88/CD79Bsingle-mut or MYD88-CD79Bco-wt, while in the non-MCD subtype, they exhibited significantly inferior OS. There was no significant disparity in PFS and OS of MYD88-CD79Bco-mut between the MCD and non-MCD subtypes. The presence of PIM1mut within the MYD88-CD79Bco-mut group correlated with better PFS, which may result from an intricate interplay of immune processes and tumor microenvironment alterations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseMyeloid Differentiation Factor 88CD79 AntigensMutationHumansPrognosisMaleFemaleTreatment OutcomeMiddle AgedAgedAdult

Substanzen

Myeloid Differentiation Factor 88CD79 AntigensCD79B protein, humanMYD88 protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Me…
  • Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 51…

ORCID-Profile: Yuankai Shi

Förderung

  • National Science and Technology Major Project for Key New Drug Development
  • Beijing Municipal Social Science Foundation

Zitieren

APA

Xie, Z., Qin, Y., Chen, X., Yang, S., Yang, J., Gui, L., Liu, P., He, X., Zhou, S., Zhang, C., Tang, L., & Shi, Y. (2024). Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes. Targeted Oncology. https://doi.org/10.1007/s11523-024-01057-w

Vancouver

Xie Z, Qin Y, Chen X, Yang S, Yang J, Gui L, et al. Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes. Targeted Oncology. 2024. doi:10.1007/s11523-024-01057-w

BibTeX
@article{Xie2024,
  author = {Xie, Zucheng and Qin, Yan and Chen, Xinrui and Yang, Sheng and Yang, Jianliang and Gui, Lin and Liu, Peng and He, Xiaohui and Zhou, Shengyu and Zhang, Changgong and Tang, Le and Shi, Yuankai},
  title = {Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes},
  journal = {Targeted Oncology},
  year = {2024},
  doi = {10.1007/s11523-024-01057-w}
}
Kostenlos starten →